Literature DB >> 9442077

Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase.

B W Hughes1, S A King, P W Allan, W B Parker, E J Sorscher.   

Abstract

Expression of Escherichia coli purine nucleoside phosphorylase (PNP) activates prodrugs and kills entire populations of mammalian cells, even when as few as 1% of the cells express this gene. This phenomenon of bystander killing has been previously investigated for herpes simplex virus-thymidine kinase (HSV-TK) and has been shown to require cell to cell contact. Using silicon rings to separate E. coli PNP expressing cells from non-expressing cells sharing the same medium, we demonstrate that bystander cell killing by E. coli PNP does not require cell-cell contact. Initially, cells expressing E. coli PNP convert the non-toxic prodrug, 6-methylpurine-2'-deoxyriboside (MeP-dR) to the highly toxic membrane permeable toxin, 6-methylpurine (MeP). As the expressing cells die, E. coli PNP is released into the culture medium, retains activity, and continues precursor conversion extracellularly (as determined by reverse phase high performance liquid chromatography of both prodrug and toxin). Bystander killing can also be observed in the absence of extracellular E. coli PNP by removing the MeP-dR prior to death of the expressing cells. In this case, 100% of cultured cells die when as few as 3% of the cells of a population express E. coli PNP. Blocking nucleoside transport with nitrobenzylthioinosine reduces MeP-dR mediated cell killing but not MeP cell killing. These mechanisms differ fundamentally from those previously reported for the HSV-TK gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9442077     DOI: 10.1074/jbc.273.4.2322

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Experimental studies on PNP suicide gene therapy of hepatoma.

Authors:  Xiaokun Cai; Junli Zhou; Jusheng Lin; Xuemei Sun; Xiulan Xue; Chao Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

2.  PRE-CLINICAL AND CLINICAL VALIDATION OF AN ANTI-CANCER MODALITY THAT ABLATES REFRACTORY, LOW GROWTH FRACTION TUMORS.

Authors:  Eric J Sorscher; Jeong S Hong; William B Parker
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

3.  Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E. coli purine nucleoside phosphorylase: palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides.

Authors:  Abdalla E A Hassan; Reham A I Abou-Elkhair; James M Riordan; Paula W Allan; William B Parker; Rashmi Khare; William R Waud; John A Montgomery; John A Secrist
Journal:  Eur J Med Chem       Date:  2011-11-04       Impact factor: 6.514

4.  Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors.

Authors:  William B Parker; Eric J Sorscher
Journal:  Curr Pharm Des       Date:  2017-11-08       Impact factor: 3.116

5.  Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.

Authors:  E L Rosenthal; T K Chung; W B Parker; P W Allan; L Clemons; D Lowman; J Hong; F R Hunt; J Richman; R M Conry; K Mannion; W R Carroll; L Nabell; E J Sorscher
Journal:  Ann Oncol       Date:  2015-04-21       Impact factor: 32.976

6.  Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.

Authors:  W B Parker; P W Allan; W R Waud; J S Hong; E J Sorscher
Journal:  Cancer Gene Ther       Date:  2011-03-11       Impact factor: 5.987

7.  Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.

Authors:  Preetinder P Singh; Swapna Joshi; Pamela J Russell; Sham Nair; Aparajita Khatri
Journal:  BMC Cancer       Date:  2011-08-24       Impact factor: 4.430

8.  Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT.

Authors:  Sepideh Afshar; Tove Olafsen; Anna M Wu; Sherie L Morrison
Journal:  J Exp Clin Cancer Res       Date:  2009-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.